Abstract:
Objective The tumorigenesis, progression, and metastasis of lung cancer are mostly governed by the immunosuppressive profile. This study aimed to explore the levels of various immunosuppressive inhibitory molecules in lung-cancer patients subjected to different chemotherapy cycles.
Methods Thirty-three patients with advanced lung cancer (ALC; stages III-IV) without receiving prior chemotherapy and 23 healthy subjects were enrolled in our study. Peripheral blood samples were collected from the patients before each chemotherapy cycle. The inhibitory markers expressed in T cells such as TIM3, PD-1, and CTLA4 were analyzed by flow cytometry.
Results The percentages of CD4+ TIM3+, CD8+ TIM3+, CD4+ PD-1+, CD8+ PD-1+, CD4+ CTLA-4+, and CD8+ CTLA-4+ T cells in the peripheral blood of the ALC patients were significantly higher compared to the controls. The percentage of CD4+ TIM3+, CD8+ TIM3+, CD4+ PD-1+, and CD8+ PD-1+ T lymphocytes in the peripheral blood of patients (n=19) who achieved PR or SD significantly decreased after five cycles of chemotherapy (P < 0.05). Similarly, the percentages of CD4+ CTLA-4+ and CD8+CTLA-4+ T cells in the patients also decreased after five cycles of treatment.
Conclusion The immune status of ALC patients was evidently suppressed. Effective chemotherapy successfully potentiated effective immune responses by downregulating inhibitory molecules in T cells.